Standard BioTools (LAB) Financials

$1.01 -0.05 (-4.25%)

Closing price 03:59 PM Eastern

Extended Trading

$1.05 +0.03 (+3.35%)

As of 06:45 PM Eastern

Annual Income Statements for Standard BioTools

This table shows Standard BioTools' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-190	-75	-185
Consolidated Net Income / (Loss)	-59	-190	-75	-139
Net Income / (Loss) Continuing Operations	-59	-190	-75	-139
Total Pre-Tax Income	-64	-193	-74	-138
Total Operating Income	-67	-116	-77	-175
Total Gross Profit	69	37	50	84
Total Revenue	131	98	106	174
Operating Revenue	131	98	106	174
Total Cost of Revenue	61	61	56	90
Operating Cost of Revenue	61	61	56	90
Total Operating Expenses	137	153	127	259
Selling, General & Admin Expense	99	102	88	157
Research & Development Expense	38	37	26	62
Restructuring Charge	-	14	14	40
Total Other Income / (Expense), net	3.80	-77	2.40	37
Interest Expense	3.82	4.33	4.57	3.32
Interest & Investment Income	0.00	2.23	5.57	20
Other Income / (Expense), net	7.62	-75	1.39	20
Income Tax Expense	-4.42	-2.83	0.45	0.57
Preferred Stock Dividends Declared	-	0.00	0.00	46
Basic Earnings per Share	($0.78)	($2.43)	($0.94)	($0.52)
Weighted Average Basic Shares Outstanding	75.79M	78.31M	79.16M	353.25M
Diluted Earnings per Share	($0.78)	($2.43)	($0.94)	($0.52)
Weighted Average Diluted Shares Outstanding	75.79M	78.31M	79.16M	353.25M
Weighted Average Basic & Diluted Shares Outstanding	77.20M	79.06M	290.12M	378.99M

This table shows Standard BioTools' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q2 2024	Q3 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	6/30/2024	9/30/2024
Net Income / (Loss) Attributable to Common Shareholders	-29	-21	-17	-17	-21	-20	-46	-27
Consolidated Net Income / (Loss)	-29	-21	-17	-17	-21	-20	-46	-27
Net Income / (Loss) Continuing Operations	-29	-21	-17	-17	-21	-20	-46	-27
Total Pre-Tax Income	-30	-21	-17	-17	-21	-20	-46	-27
Total Operating Income	-29	-21	-17	-17	-21	-21	-51	-32
Total Gross Profit	9.22	11	12	14	11	13	15	23
Total Revenue	26	27	25	28	25	28	37	45
Operating Revenue	26	27	25	28	25	28	37	45
Total Cost of Revenue	16	16	13	14	14	15	22	22
Operating Cost of Revenue	16	16	13	14	14	15	22	22
Total Operating Expenses	38	32	29	31	32	35	65	55
Selling, General & Admin Expense	26	15	21	23	22	21	38	34
Research & Development Expense	8.49	7.43	6.43	6.18	6.37	6.97	19	13
Restructuring Charge	3.42	-	1.15	2.27	3.66	6.48	8.53	7.42
Total Other Income / (Expense), net	-1.11	0.34	0.01	0.71	0.23	1.45	4.86	4.90
Interest & Investment Income	0.00	62	0.07	0.24	0.34	4.92	4.44	3.94
Other Income / (Expense), net	-0.06	-61	-0.06	0.47	-0.12	1.10	0.41	0.96
Income Tax Expense	-0.71	0.07	0.26	0.30	0.05	-0.16	0.06	0.12
Preferred Stock Dividends Declared	-	-	0.00	0.00	0.00	-	0.00	0.00
Basic Earnings per Share	($0.37)	($0.25)	($0.21)	($0.22)	($0.27)	($0.24)	($0.12)	($0.07)
Weighted Average Basic Shares Outstanding	78.90M	78.31M	79.08M	78.67M	79.15M	79.16M	372.33M	371.54M
Diluted Earnings per Share	($0.37)	($0.25)	($0.21)	($0.22)	($0.27)	($0.24)	($0.12)	($0.07)
Weighted Average Diluted Shares Outstanding	78.90M	78.31M	79.08M	78.67M	79.15M	79.16M	372.33M	371.54M
Weighted Average Basic & Diluted Shares Outstanding	79.30M	79.06M	78.38M	78.96M	79.40M	290.12M	371.15M	372.26M

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-40	53	-30	116
Net Cash From Operating Activities	-44	-89	-43	-143
Net Cash From Continuing Operating Activities	-44	-89	-43	-143
Net Income / (Loss) Continuing Operations	-59	-190	-75	-139
Consolidated Net Income / (Loss)	-59	-190	-75	-139
Depreciation Expense	3.65	3.50	3.98	13
Amortization Expense	13	11	9.94	-3.09
Non-Cash Adjustments To Reconcile Net Income	18	101	15	8.31
Changes in Operating Assets and Liabilities, net	-19	-14	2.73	-22
Net Cash From Investing Activities	-12	-88	20	363
Net Cash From Continuing Investing Activities	-12	-88	20	363
Purchase of Property, Plant & Equipment	-13	-3.83	-2.83	-8.36
Acquisitions	-	0.00	0.00	-1.39
Purchase of Investments	0.00	-137	-95	-256
Sale and/or Maturity of Investments	0.00	53	118	349
Other Investing Activities, net	1.32	0.00	0.00	280
Net Cash From Financing Activities	16	231	-6.81	-103
Net Cash From Continuing Financing Activities	16	231	-6.81	-103
Repayment of Debt	-0.50	-6.84	-2.08	-64
Repurchase of Common Equity	-0.08	-13	-5.41	-40
Issuance of Debt	17	25	0.00	0.00
Issuance of Preferred Equity	0.00	225	0.00	0.00
Issuance of Common Equity	1.49	0.82	0.72	0.92
Other Financing Activities, net	-1.79	-0.11	-0.04	0.69
Effect of Exchange Rate Changes	-0.02	-0.40	0.03	-0.79
Cash Interest Paid	3.15	3.49	3.82	3.09
Cash Income Taxes Paid	2.09	0.31	0.80	0.61

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-14	21	32	29	-63	-28	-59	-43
Net Cash From Operating Activities	-25	-19	-8.49	-9.33	-11	-14	-28	-14
Net Cash From Continuing Operating Activities	-25	-19	-8.49	-9.33	-11	-14	-28	-14
Net Income / (Loss) Continuing Operations	-29	-21	-17	-17	-21	-20	-27	-34
Consolidated Net Income / (Loss)	-29	-21	-17	-17	-21	-20	-27	-34
Depreciation Expense	0.80	0.82	0.86	0.83	1.19	1.11	3.15	3.14
Amortization Expense	3.01	1.50	2.64	2.81	2.63	1.86	-1.05	-0.32
Non-Cash Adjustments To Reconcile Net Income	7.14	2.76	3.54	3.36	6.60	1.23	10	3.40
Changes in Operating Assets and Liabilities, net	-6.13	-3.42	1.32	0.71	-0.83	1.52	-13	14
Net Cash From Investing Activities	11	40	43	40	-50	-13	-31	26
Net Cash From Continuing Investing Activities	11	40	43	40	-50	-13	-31	26
Purchase of Property, Plant & Equipment	-1.26	-0.76	-1.01	-0.84	-0.91	-0.08	-2.26	-3.38
Purchase of Investments	-	-	-6.84	-	-49	-39	-79	-30
Sale and/or Maturity of Investments	12	41	51	41	-	26	50	60
Net Cash From Financing Activities	-0.01	-0.27	-2.56	-2.08	-1.16	-1.00	-0.00	-55
Net Cash From Continuing Financing Activities	-0.01	-0.27	-2.56	-2.08	-1.16	-1.00	-0.00	-55
Repayment of Debt	-	-	0.00	-	-0.83	-1.25	-	-55
Issuance of Common Equity	-	0.32	-	-	-	0.40	-	0.49
Other Financing Activities, net	-0.01	-0.03	-0.09	-0.04	0.07	0.02	-0.00	-0.01
Effect of Exchange Rate Changes	-0.28	0.32	0.02	-0.07	-0.15	0.23	-0.41	-0.27
Cash Interest Paid	0.17	1.65	0.23	1.69	0.25	1.65	0.00	1.44
Cash Income Taxes Paid	-0.39	0.06	0.31	0.21	0.12	0.17	0.06	0.20

This table presents Standard BioTools' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	275	390	323	612
Total Current Assets	72	209	158	376
Cash & Equivalents	28	81	52	167
Short-Term Investments	0.00	84	63	126
Accounts Receivable	18	17	20	34
Inventories, net	21	21	21	41
Prepaid Expenses	4.47	4.28	3.13	8.66
Plant, Property, & Equipment, net	28	26	24	43
Total Noncurrent Assets	175	156	141	194
Goodwill	106	106	106	111
Intangible Assets	28	13	1.40	29
Other Noncurrent Operating Assets	41	37	33	54
Total Liabilities & Shareholders' Equity	275	390	323	612
Total Liabilities	181	161	160	141
Total Current Liabilities	50	43	109	66
Short-Term Debt	6.84	2.08	60	0.00
Accounts Payable	11	7.91	9.24	12
Accrued Expenses	8.67	6.18	21	31
Current Deferred Revenue	15	14	15	17
Other Current Liabilities	3.05	3.68	4.32	6.23
Total Noncurrent Liabilities	131	117	51	75
Long-Term Debt	64	63	3.98	0.30
Noncurrent Deferred Revenue	5.97	3.82	3.52	33
Noncurrent Deferred & Payable Income Tax Liabilities	4.33	1.06	0.84	1.08
Other Noncurrent Operating Liabilities	57	49	42	41
Commitments & Contingencies	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	311	311	0.00
Total Equity & Noncontrolling Interests	95	-81	-148	472
Total Preferred & Common Equity	95	-81	-148	472
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	95	-81	-148	472
Common Stock	832	847	861	1,703
Retained Earnings	-736	-926	-1,001	-1,186
Treasury Stock	0.00	-0.56	-5.98	-46
Accumulated Other Comprehensive Income / (Loss)	-0.91	-1.90	-2.22	1.23

This table presents Standard BioTools' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	6/30/2024	9/30/2024
Total Assets	415	372	356	339	709	682
Total Current Assets	229	195	183	171	480	454
Cash & Equivalents	60	114	142	80	270	211
Short-Term Investments	125	41	0.00	49	125	156
Accounts Receivable	17	15	15	17	32	35
Inventories, net	22	23	22	22	43	43
Prepaid Expenses	4.61	3.37	3.57	3.40	10	9.32
Plant, Property, & Equipment, net	27	25	25	25	43	42
Total Noncurrent Assets	159	152	148	144	186	186
Goodwill	106	106	106	106	106	106
Intangible Assets	15	9.80	7.00	4.20	24	23
Other Noncurrent Operating Assets	38	36	35	34	56	56
Total Liabilities & Shareholders' Equity	415	372	356	339	709	682
Total Liabilities	166	158	158	160	198	192
Total Current Liabilities	46	44	47	52	124	121
Short-Term Debt	0.83	3.33	4.58	5.00	55	55
Accounts Payable	9.31	6.11	6.09	7.33	13	11
Accrued Expenses	6.91	6.88	7.18	10	32	32
Current Deferred Revenue	15	15	15	15	19	17
Other Current Liabilities	3.52	3.76	3.91	3.98	5.85	6.12
Total Noncurrent Liabilities	120	114	111	108	75	72
Long-Term Debt	64	62	61	60	0.30	0.30
Noncurrent Deferred Revenue	4.43	3.83	3.79	3.47	33	33
Noncurrent Deferred & Payable Income Tax Liabilities	0.62	1.05	1.05	1.02	0.84	0.84
Other Noncurrent Operating Liabilities	51	47	46	44	40	38
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	311	311	311	311	0.00	0.00
Total Equity & Noncontrolling Interests	-63	-97	-113	-132	510	489
Total Preferred & Common Equity	-63	-97	-113	-132	510	489
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-63	-97	-113	-132	510	489
Common Stock	845	850	854	857	1,683	1,689
Retained Earnings	-905	-943	-960	-981	-1,125	-1,152
Treasury Stock	-	-3.03	-5.40	-5.80	-46	-46
Accumulated Other Comprehensive Income / (Loss)	-2.61	-1.33	-1.55	-1.95	-1.50	-1.41

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-
Revenue Growth	-5.47%	-24.99%	8.57%	64.03%
EBITDA Growth	-36.20%	-304.36%	65.27%	-137.83%
EBIT Growth	-18.42%	-218.90%	60.59%	-106.35%
NOPAT Growth	-32.18%	-72.26%	34.08%	-128.77%
Net Income Growth	-11.73%	-220.91%	60.73%	-86.03%
EPS Growth	-5.41%	-211.54%	61.32%	44.68%
Operating Cash Flow Growth	-185.79%	-102.83%	51.56%	-231.40%
Free Cash Flow Firm Growth	-410.55%	-22.44%	49.97%	-419.87%
Invested Capital Growth	9.97%	-6.05%	-13.25%	60.21%
Revenue Q/Q Growth	-4.63%	-10.30%	1.11%	0.00%
EBITDA Q/Q Growth	13.42%	-73.03%	-2.61%	0.00%
EBIT Q/Q Growth	10.44%	-61.57%	-0.94%	0.00%
NOPAT Q/Q Growth	7.72%	-9.26%	-0.36%	0.00%
Net Income Q/Q Growth	12.67%	-6.39%	1.41%	0.00%
EPS Q/Q Growth	14.29%	-5.65%	1.05%	0.00%
Operating Cash Flow Q/Q Growth	-8.01%	-15.78%	10.58%	0.00%
Free Cash Flow Firm Q/Q Growth	-15.85%	-6.74%	10.09%	0.00%
Invested Capital Q/Q Growth	2.33%	0.65%	-3.00%	0.00%
Profitability Metrics	-	-	-	-
Gross Margin	53.13%	37.83%	47.44%	48.31%
EBITDA Margin	-33.42%	-180.17%	-57.64%	-83.57%
Operating Margin	-51.66%	-118.64%	-72.03%	-100.46%
EBIT Margin	-45.82%	-194.82%	-70.73%	-88.97%
Profit (Net Income) Margin	-45.36%	-194.08%	-70.21%	-79.62%
Tax Burden Percent	93.05%	98.53%	100.61%	100.41%
Interest Burden Percent	106.39%	101.10%	98.66%	89.12%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-36.05%	-61.14%	-44.55%	-84.32%
ROIC Less NNEP Spread (ROIC-NNEP)	-120.97%	311.97%	-16.92%	-74.88%
Return on Net Nonoperating Assets (RNNOA)	-14.65%	-56.07%	6.56%	40.57%
Return on Equity (ROE)	-50.71%	-117.21%	-37.99%	-43.75%
Cash Return on Invested Capital (CROIC)	-45.55%	-54.90%	-30.36%	-130.59%
Operating Return on Assets (OROA)	-19.95%	-57.35%	-21.09%	-33.18%
Return on Assets (ROA)	-19.75%	-57.13%	-20.93%	-29.70%
Return on Common Equity (ROCE)	-50.71%	-4.74%	22.19%	-22.30%
Return on Equity Simple (ROE_SIMPLE)	-62.62%	233.34%	50.43%	-29.44%
Net Operating Profit after Tax (NOPAT)	-47	-81	-54	-123
NOPAT Margin	-36.16%	-83.05%	-50.42%	-70.32%
Net Nonoperating Expense Percent (NNEP)	84.92%	-373.11%	-27.63%	-9.43%
Return On Investment Capital (ROIC_SIMPLE)	-	490.76%	63.43%	-25.99%
Cost of Revenue to Revenue	46.87%	62.17%	52.56%	51.69%
SG&A Expenses to Revenue	75.73%	104.43%	82.32%	89.78%
R&D to Revenue	29.06%	38.17%	24.40%	35.78%
Operating Expenses to Revenue	104.79%	156.47%	119.48%	148.77%
Earnings before Interest and Taxes (EBIT)	-60	-191	-75	-155
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-44	-176	-61	-146
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	3.17	0.00	0.00	1.38
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	1.97
Price to Revenue (P/Rev)	2.30	0.95	1.65	3.73
Price to Earnings (P/E)	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.50	2.35	3.89	2.00
Enterprise Value to Revenue (EV/Rev)	2.62	3.09	4.09	2.06
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	0.75	0.28	0.39	0.00
Long-Term Debt to Equity	0.68	0.27	0.02	0.00
Financial Leverage	0.12	-0.18	-0.39	-0.54
Leverage Ratio	2.57	2.05	1.82	1.47
Compound Leverage Factor	2.73	2.07	1.79	1.31
Debt to Total Capital	42.89%	22.02%	28.01%	0.06%
Short-Term Debt to Total Capital	4.13%	0.71%	26.26%	0.00%
Long-Term Debt to Total Capital	38.76%	21.31%	1.76%	0.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	105.62%	137.29%	0.00%
Common Equity to Total Capital	57.11%	-27.65%	-65.30%	99.94%
Debt to EBITDA	-1.63	-0.37	-1.04	0.00
Net Debt to EBITDA	-0.98	0.57	0.84	2.01
Long-Term Debt to EBITDA	-1.47	-0.36	-0.07	0.00
Debt to NOPAT	-1.50	-0.80	-1.18	0.00
Net Debt to NOPAT	-0.90	1.24	0.96	2.39
Long-Term Debt to NOPAT	-1.36	-0.77	-0.07	0.00
Altman Z-Score	-2.89	-3.83	-3.94	0.12
Noncontrolling Interest Sharing Ratio	0.00%	95.95%	158.40%	49.02%
Liquidity Ratios	-	-	-	-
Current Ratio	1.45	4.81	1.45	5.70
Quick Ratio	0.94	4.21	1.23	4.95
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	-60	-73	-37	-190
Operating Cash Flow to CapEx	-332.18%	-2,336.47%	-1,529.04%	-1,716.98%
Free Cash Flow to Firm to Interest Expense	-15.61	-16.87	-8.00	-57.30
Operating Cash Flow to Interest Expense	-11.53	-20.64	-9.48	-43.26
Operating Cash Flow Less CapEx to Interest Expense	-14.99	-21.52	-10.10	-45.78
Efficiency Ratios	-	-	-	-
Asset Turnover	0.44	0.29	0.30	0.37
Accounts Receivable Turnover	5.97	5.50	5.76	6.55
Inventory Turnover	3.02	2.88	2.66	2.94
Fixed Asset Turnover	5.73	3.65	4.27	5.23
Accounts Payable Turnover	6.18	6.58	6.52	8.38
Days Sales Outstanding (DSO)	61.14	66.33	63.40	55.73
Days Inventory Outstanding (DIO)	120.80	126.76	137.16	124.01
Days Payable Outstanding (DPO)	59.10	55.49	56.00	43.55
Cash Conversion Cycle (CCC)	122.83	137.60	144.56	136.19
Capital & Investment Metrics	-	-	-	-
Invested Capital	137	129	112	179
Invested Capital Turnover	1.00	0.74	0.88	1.20
Increase / (Decrease) in Invested Capital	12	-8.30	-17	67
Enterprise Value (EV)	342	303	435	359
Market Capitalization	300	93	175	651
Book Value per Share	$1.24	($1.03)	($1.86)	$1.27
Tangible Book Value per Share	($0.52)	($2.53)	($3.22)	$0.89
Total Capital	166	295	227	472
Total Debt	71	65	64	0.30
Total Long-Term Debt	64	63	3.98	0.30
Net Debt	43	-101	-51	-293
Capital Expenditures (CapEx)	13	3.83	2.83	8.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.89	1.67	-6.48	17
Debt-free Net Working Capital (DFNWC)	29	167	108	310
Net Working Capital (NWC)	22	165	49	310
Net Nonoperating Expense (NNE)	12	109	21	16
Net Nonoperating Obligations (NNO)	43	-101	-51	-293
Total Depreciation and Amortization (D&A)	16	14	14	9.43
Debt-free, Cash-free Net Working Capital to Revenue	0.68%	1.71%	-6.09%	9.81%
Debt-free Net Working Capital to Revenue	22.47%	170.96%	101.95%	177.71%
Net Working Capital to Revenue	17.23%	168.84%	45.97%	177.71%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	($0.78)	($2.43)	($0.94)	($0.52)
Adjusted Weighted Average Basic Shares Outstanding	75.79M	78.31M	79.16M	353.25M
Adjusted Diluted Earnings per Share	($0.78)	($2.43)	($0.94)	($0.52)
Adjusted Weighted Average Diluted Shares Outstanding	75.79M	78.31M	79.16M	353.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.20M	79.06M	290.12M	378.99M
Normalized Net Operating Profit after Tax (NOPAT)	-47	-72	-44	-94
Normalized NOPAT Margin	-36.16%	-73.34%	-41.50%	-54.08%
Pre Tax Income Margin	-48.75%	-196.97%	-69.78%	-79.29%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	-15.65	-44.06	-16.47	-46.80
NOPAT to Interest Expense	-12.35	-18.78	-11.74	-36.99
EBIT Less CapEx to Interest Expense	-19.12	-44.94	-17.09	-49.32
NOPAT Less CapEx to Interest Expense	-15.82	-19.66	-12.36	-39.51
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.13%	-6.90%	-7.25%	-29.15%

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q2 2024	Q3 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	6/30/2024	9/30/2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	-10.03%	-29.38%	-5.23%	47.34%	-1.09%	4.32%	34.48%	77.27%
EBITDA Growth	-147.65%	-1,463.05%	61.15%	64.66%	30.90%	78.23%	-275.53%	-64.05%
EBIT Growth	-103.47%	-792.95%	56.23%	59.37%	26.82%	75.23%	-195.04%	-44.51%
NOPAT Growth	-48.01%	-87.51%	39.67%	54.75%	27.06%	-1.30%	-189.52%	-49.81%
Net Income Growth	-112.57%	-121.05%	77.92%	73.18%	28.64%	5.13%	-168.30%	-28.29%
EPS Growth	-105.56%	-108.33%	78.79%	73.17%	27.03%	4.00%	45.45%	74.07%
Operating Cash Flow Growth	-159.23%	-173.94%	45.57%	68.89%	53.63%	26.69%	0.00%	-144.21%
Free Cash Flow Firm Growth	-1.79%	68.11%	-382.28%	72.74%	85.76%	132.46%	-1,346.95%	-4,079.08%
Invested Capital Growth	-4.49%	-6.05%	35.23%	-4.98%	-9.98%	-13.25%	41.24%	54.60%
Revenue Q/Q Growth	36.58%	5.36%	-7.04%	10.14%	-8.31%	11.12%	0.00%	20.87%
EBITDA Q/Q Growth	33.03%	-214.74%	16.55%	-1.43%	-30.94%	0.86%	0.00%	42.80%
EBIT Q/Q Growth	30.41%	-181.51%	14.98%	-1.99%	-25.34%	4.70%	0.00%	38.61%
NOPAT Q/Q Growth	24.73%	27.27%	21.40%	-5.16%	-21.34%	-1.01%	0.00%	37.22%
Net Income Q/Q Growth	53.69%	29.16%	19.20%	-1.17%	-23.22%	5.82%	0.00%	41.08%
EPS Q/Q Growth	54.88%	32.43%	16.00%	-4.76%	-22.73%	11.11%	0.00%	41.67%
Operating Cash Flow Q/Q Growth	17.93%	22.06%	55.76%	-9.95%	-22.33%	-23.21%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	33.78%	54.69%	-580.25%	86.65%	65.39%	203.26%	0.00%	0.05%
Invested Capital Q/Q Growth	0.73%	0.65%	-3.31%	-3.07%	-4.58%	-3.00%	0.00%	4.45%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	35.95%	41.33%	48.89%	49.17%	43.97%	47.58%	40.07%	51.73%
EBITDA Margin	-98.58%	-294.49%	-52.37%	-48.23%	-68.87%	-61.45%	-134.68%	-63.74%
Operating Margin	-113.18%	-78.13%	-66.06%	-63.07%	-83.46%	-75.87%	-135.79%	-70.53%
EBIT Margin	-113.43%	-303.07%	-66.29%	-61.39%	-83.92%	-71.97%	-134.68%	-68.40%
Profit (Net Income) Margin	-114.74%	-77.14%	-67.05%	-61.59%	-82.77%	-70.16%	-122.88%	-59.90%
Tax Burden Percent	97.63%	100.34%	101.59%	101.80%	100.24%	99.19%	100.12%	100.44%
Interest Burden Percent	103.61%	25.37%	99.57%	98.56%	98.40%	98.28%	91.13%	87.19%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-66.01%	-40.27%	-41.19%	-37.55%	-50.50%	-46.92%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-44.76%	-19.45%	12.65%	-33.24%	-43.82%	-40.61%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	11.03%	3.50%	-1.04%	15.77%	18.91%	15.74%	0.00%	0.00%
Return on Equity (ROE)	-54.98%	-36.77%	-42.23%	-21.79%	-31.60%	-31.19%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	-52.21%	-54.90%	-97.95%	-42.43%	-33.41%	-30.36%	0.00%	0.00%
Operating Return on Assets (OROA)	-35.53%	-89.21%	-19.89%	-16.25%	-23.40%	-21.46%	0.00%	0.00%
Return on Assets (ROA)	-35.94%	-22.71%	-20.12%	-16.30%	-23.09%	-20.92%	0.00%	0.00%
Return on Common Equity (ROCE)	-5.78%	-1.49%	13.42%	6.97%	14.36%	18.21%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	284.77%	0.00%	134.48%	74.22%	57.49%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-20	-15	-12	-12	-15	-15	-35	-22
NOPAT Margin	-79.23%	-54.69%	-46.24%	-44.15%	-58.42%	-53.11%	-95.05%	-49.37%
Net Nonoperating Expense Percent (NNEP)	-21.25%	-20.81%	-53.84%	-4.31%	-6.69%	-6.31%	-4.97%	-2.52%
Cost of Revenue to Revenue	64.05%	58.67%	51.11%	50.84%	56.03%	52.42%	59.93%	48.27%
SG&A Expenses to Revenue	102.71%	55.46%	84.78%	81.69%	87.88%	75.76%	101.26%	76.50%
R&D to Revenue	33.09%	27.48%	25.59%	22.35%	25.11%	24.71%	51.67%	29.26%
Operating Expenses to Revenue	149.13%	119.46%	114.95%	112.24%	127.43%	123.45%	175.86%	122.26%
Earnings before Interest and Taxes (EBIT)	-29	-82	-17	-17	-21	-20	-50	-31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-25	-80	-13	-13	-17	-17	-50	-29
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	1.29	1.46
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	1.73	1.99
Price to Revenue (P/Rev)	0.79	0.95	1.60	1.43	2.18	1.65	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.17	2.35	3.02	3.19	4.13	3.89	1.87	2.27
Enterprise Value to Revenue (EV/Rev)	2.54	3.09	3.89	3.66	4.53	4.09	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.26	0.28	0.30	0.33	0.36	0.39	0.11	0.11
Long-Term Debt to Equity	0.26	0.27	0.29	0.31	0.33	0.02	0.00	0.00
Financial Leverage	-0.25	-0.18	-0.08	-0.47	-0.43	-0.39	-0.59	-0.56
Leverage Ratio	2.00	2.05	2.72	1.69	1.76	1.82	1.50	1.53
Compound Leverage Factor	2.08	0.52	2.71	1.67	1.73	1.78	1.37	1.33
Debt to Total Capital	20.66%	22.02%	23.31%	24.80%	26.46%	28.01%	9.74%	10.14%
Short-Term Debt to Total Capital	0.27%	0.71%	1.19%	1.74%	2.05%	26.26%	9.69%	10.08%
Long-Term Debt to Total Capital	20.40%	21.31%	22.11%	23.06%	24.41%	1.76%	0.05%	0.05%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	99.37%	105.62%	111.49%	118.30%	127.50%	137.29%	0.00%	0.00%
Common Equity to Total Capital	-20.03%	-27.65%	-34.80%	-43.09%	-53.96%	-65.30%	90.26%	89.86%
Debt to EBITDA	-0.63	-0.37	-0.71	-0.97	-1.08	-1.04	0.00	0.00
Net Debt to EBITDA	1.18	0.57	0.97	1.14	1.08	0.84	0.00	0.00
Long-Term Debt to EBITDA	-0.63	-0.36	-0.67	-0.90	-1.00	-0.07	0.00	0.00
Debt to NOPAT	-0.87	-0.80	-0.88	-1.11	-1.21	-1.18	0.00	0.00
Net Debt to NOPAT	1.62	1.24	1.21	1.31	1.20	0.96	0.00	0.00
Long-Term Debt to NOPAT	-0.86	-0.77	-0.84	-1.03	-1.12	-0.07	0.00	0.00
Altman Z-Score	-2.18	-2.91	-2.36	-2.60	-2.66	-3.37	0.00	0.00
Noncontrolling Interest Sharing Ratio	89.48%	95.95%	131.77%	131.98%	145.43%	158.40%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	4.96	4.81	4.45	3.91	3.30	1.45	3.88	3.76
Quick Ratio	4.39	4.21	3.86	3.36	2.81	1.23	3.45	3.33
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14	-6.48	-44	-5.89	-2.04	2.10	-85	-85
Operating Cash Flow to CapEx	-1,947.07%	-2,540.53%	-840.10%	-1,113.25%	-1,260.99%	-18,026.92%	0.00%	-1,235.88%
Free Cash Flow to Firm to Interest Expense	-13.63	-5.45	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-23.46	-16.12	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-24.67	-16.75	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.29	0.30	0.26	0.28	0.30	0.00	0.00
Accounts Receivable Turnover	7.04	5.50	6.45	8.09	6.21	5.76	0.00	0.00
Inventory Turnover	2.72	2.88	2.60	2.64	2.60	2.66	0.00	0.00
Fixed Asset Turnover	3.94	3.65	3.66	4.07	4.11	4.27	0.00	0.00
Accounts Payable Turnover	6.28	6.58	6.39	7.84	6.85	6.52	0.00	0.00
Days Sales Outstanding (DSO)	51.86	66.33	56.56	45.09	58.74	63.40	0.00	0.00
Days Inventory Outstanding (DIO)	134.40	126.76	140.43	138.37	140.55	137.16	0.00	0.00
Days Payable Outstanding (DPO)	58.14	55.49	57.16	46.58	53.28	56.00	0.00	0.00
Cash Conversion Cycle (CCC)	128.12	137.60	139.82	136.88	146.01	144.56	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	128	129	125	121	115	112	171	178
Invested Capital Turnover	0.83	0.74	0.89	0.85	0.86	0.88	0.00	0.00
Increase / (Decrease) in Invested Capital	-6.02	-8.30	32	-6.33	-13	-17	50	63
Enterprise Value (EV)	277	303	376	385	476	435	319	405
Market Capitalization	87	93	154	151	229	175	659	716
Book Value per Share	($0.80)	($1.03)	($1.23)	($1.45)	($1.67)	($1.86)	$1.37	$1.32
Tangible Book Value per Share	($2.34)	($2.53)	($2.70)	($2.89)	($3.07)	($3.22)	$1.02	$0.97
Total Capital	313	295	279	263	244	227	565	545
Total Debt	65	65	65	65	65	64	55	55
Total Long-Term Debt	64	63	62	61	60	3.98	0.30	0.30
Net Debt	-120	-101	-89	-77	-64	-51	-340	-311
Capital Expenditures (CapEx)	1.26	0.76	1.01	0.84	0.91	0.08	0.00	2.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.49	1.67	-0.06	-1.49	-4.91	-6.48	16	22
Debt-free Net Working Capital (DFNWC)	184	167	154	141	124	108	411	388
Net Working Capital (NWC)	183	165	151	136	119	49	356	333
Net Nonoperating Expense (NNE)	9.11	6.07	5.23	4.83	6.18	4.81	10	4.74
Net Nonoperating Obligations (NNO)	-120	-101	-89	-77	-64	-51	-340	-311
Total Depreciation and Amortization (D&A)	3.81	2.32	3.50	3.64	3.82	2.97	0.00	2.10
Debt-free, Cash-free Net Working Capital to Revenue	-1.36%	1.71%	-0.07%	-1.41%	-4.67%	-6.09%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	168.22%	170.96%	159.97%	133.53%	117.84%	101.95%	0.00%	0.00%
Net Working Capital to Revenue	167.46%	168.84%	156.52%	129.19%	113.09%	45.97%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.37)	($0.25)	($0.21)	($0.22)	($0.27)	($0.24)	($0.12)	($0.07)
Adjusted Weighted Average Basic Shares Outstanding	78.90M	78.31M	79.08M	78.67M	79.15M	79.16M	372.33M	371.54M
Adjusted Diluted Earnings per Share	($0.37)	($0.25)	($0.21)	($0.22)	($0.27)	($0.24)	($0.12)	($0.07)
Adjusted Weighted Average Diluted Shares Outstanding	78.90M	78.31M	79.08M	78.67M	79.15M	79.16M	372.33M	371.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	79.30M	79.06M	78.38M	78.96M	79.40M	290.12M	371.15M	372.26M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-15	-11	-11	-12	-10	-29	-17
Normalized NOPAT Margin	-69.89%	-54.69%	-43.04%	-38.41%	-48.31%	-37.02%	-79.00%	-37.82%
Pre Tax Income Margin	-117.52%	-76.88%	-66.01%	-60.50%	-82.58%	-70.73%	-122.73%	-59.64%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-27.73	-68.82	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-19.37	-12.42	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-28.94	-69.45	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-20.57	-13.05	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-7.05%	-6.90%	-11.92%	-6.42%	-7.66%	-7.25%	0.00%	0.00%

Frequently Asked Questions About Standard BioTools' Financials

When does Standard BioTools's fiscal year end?

According to the most recent income statement we have on file, Standard BioTools' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Standard BioTools' net income changed over the last 3 years?

Standard BioTools' net income appears to be on an upward trend, with a most recent value of -$138.89 million in 2024, rising from -$59.24 million in 2021. The previous period was -$74.66 million in 2023. See Standard BioTools' forecast for analyst expectations on what’s next for the company.

What is Standard BioTools's operating income?

Standard BioTools's total operating income in 2024 was -$175.24 million, based on the following breakdown:

Total Gross Profit: $84.26 million
Total Operating Expenses: $259.50 million

How has Standard BioTools revenue changed over the last 3 years?

Over the last 3 years, Standard BioTools' total revenue changed from $130.58 million in 2021 to $174.43 million in 2024, a change of 33.6%.

How much debt does Standard BioTools have?

Standard BioTools' total liabilities were at $140.62 million at the end of 2024, a 12.0% decrease from 2023, and a 22.1% decrease since 2021.

How much cash does Standard BioTools have?

In the past 3 years, Standard BioTools' cash and equivalents has ranged from $28.45 million in 2021 to $166.73 million in 2024, and is currently $166.73 million as of their latest financial filing in 2024.

How has Standard BioTools' book value per share changed over the last 3 years?

Over the last 3 years, Standard BioTools' book value per share changed from 1.24 in 2021 to 1.27 in 2024, a change of 2.5%.

Related Companies

This page (NASDAQ:LAB) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Financials

Frequently Asked Questions About Standard BioTools' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Financials

Annual Income Statements for Standard BioTools

Quarterly Income Statements for Standard BioTools

Annual Cash Flow Statements for Standard BioTools

Quarterly Cash Flow Statements for Standard BioTools

Annual Balance Sheets for Standard BioTools

Quarterly Balance Sheets for Standard BioTools

Annual Metrics and Ratios for Standard BioTools

Quarterly Metrics and Ratios for Standard BioTools

Frequently Asked Questions About Standard BioTools' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools